- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: Hot cell.
Displaying page 1 of 1.
EudraCT Number: 2008-002152-26 | Sponsor Protocol Number: ISRCTN86894066 | Start Date*: 2009-01-20 | |||||||||||
Sponsor Name:The Royal Marsden Foundation Trust and The Institute of Cancer Research | |||||||||||||
Full Title: Randomised double-blind controlled phase III trial of hyperbaric oxygen therapy in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | |||||||||||||
Medical condition: Chronic radiation-induced gastrointestinal symptoms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000328-85 | Sponsor Protocol Number: FINNHT1 | Start Date*: 2017-05-18 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Helsinki University Hospital, Obstetrics and Gynecology | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Randomized comparative trial between abrupt and tapered mode of discontinuation of longterm hormone therapy: Impact on endothelial function, recurrence of vasomotor symptoms and quality of life | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: We will assess the effects of hormone therapy termination on endothelial function using biophysical (flow-mediated dilation, peripheral artery tonometry) and biochemical markers. We will compare th... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Prematurely Ended) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001624-17 | Sponsor Protocol Number: 210321 | Start Date*: 2021-07-21 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: Safety of oral micronized progesterone versus norethisterone acetate in continuous combination with oral estrogen as menopausal hormone therapy – a double-blind randomized study- PROBES study (Prog... | ||
Medical condition: Climacteric symptoms | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004403-31 | Sponsor Protocol Number: MITOEND-3 | Start Date*: 2022-03-24 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE | |||||||||||||
Full Title: MITO END-3: A randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (stage III-IV) or recurrent endometrial cancer | |||||||||||||
Medical condition: advanced (stage III-IV) or recurrent endometrial cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004311-23 | Sponsor Protocol Number: HOTstudy_Thomas11 | Start Date*: 2011-11-29 | ||||||||||||||||
Sponsor Name:University of Edinburgh [...] | ||||||||||||||||||
Full Title: A randomised, placebo controlled trial to study the effect of heme-arginate on heme-oxygenase-1 induction and renal function in recipients of deceased donor renal transplants. | ||||||||||||||||||
Medical condition: Ischaemia-reperfusion injury in renal transplantation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2013-004055-20 | Sponsor Protocol Number: ICR-CTSU/2013/10040 | Start Date*: 2014-09-23 | ||||||||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | ||||||||||||||||||
Full Title: A phase II randomised trial of biomarkers to assess (dose-) response in patients with metastatic castration resistant prostate cancer treated with radium-223. | ||||||||||||||||||
Medical condition: Castrate resistant prostate cancer with bone metastases. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-003913-21 | Sponsor Protocol Number: NL78575.018.21 | Start Date*: 2022-07-20 | ||||||||||||||||||||||||||
Sponsor Name:Amsterdam UMC | ||||||||||||||||||||||||||||
Full Title: A Prospective, Open-label Pilot Study to Evaluate Effector mechanisms of Hyperbaric Oxygen Therapy in Patients with Moderate-to-Severe Ulcerative Colitis: The PARADOX study | ||||||||||||||||||||||||||||
Medical condition: Ulcerative colitis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004677-20 | Sponsor Protocol Number: Gemtax IV | Start Date*: 2006-03-17 |
Sponsor Name:University of Heidelberg, Klinikum Mannheim, Dep Surgery/Thoracical Oncology | ||
Full Title: Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stag... | ||
Medical condition: Lung cancer remains the leading cause of cancer-related death in men and has increased its incidence in women over the past decades (protocol page 9). Data from both meta-analysis and clinical tria... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) LT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004764-10 | Sponsor Protocol Number: EPI-506-CS-0001 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:Essa Pharmaceuticals Corp. | |||||||||||||
Full Title: A Phase 1/2 Open-label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral EPI-506 in Patients with Metastatic Castration-resistant Prostate Cancer | |||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002714-23 | Sponsor Protocol Number: LLC1114 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Fondazione G.I.M.EM.A. Onlus Gruppo Italiano Malattie Ematologiche dell'Adulto | |||||||||||||
Full Title: A phase 2 multicenter study to assess the activity and the safety of front-line Ibrutinib plus Rituximab (IR) in unfit patients with Chronic Lymphocytic Leukemia (CLL). | |||||||||||||
Medical condition: Chronic Lymphocytic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000916-27 | Sponsor Protocol Number: RG_19-030 | Start Date*: 2020-11-12 | ||||||||||||||||
Sponsor Name:University of Birmingham | ||||||||||||||||||
Full Title: Investigation into the combination of PLX2853 with ruxolitinib in patients with intermediate-2 or high risk myelofibrosis not receiving an adequate response with ruxolitinib alone. | ||||||||||||||||||
Medical condition: Myelofibrosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002021-28 | Sponsor Protocol Number: PLX124-04 | Start Date*: 2020-09-24 | |||||||||||||||||||||
Sponsor Name:Plexxikon Inc. | |||||||||||||||||||||||
Full Title: A Multicenter, Open-Label, Parallel, Phase 1b/2a Study of PLX2853 in Combination with Abiraterone Acetate and Prednisone and Phase 1b/2a Study of PLX2853 in Combination with Olaparib in Subjects wi... | |||||||||||||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer (mCRPC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002741-18 | Sponsor Protocol Number: GS-US-611-6273 | Start Date*: 2022-12-19 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression | |||||||||||||
Medical condition: Coronavirus disease 2019 (COVID-19) in patients who have a high risk of developing serious or severe illness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) HU (Completed) ES (Ongoing) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
